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Background: Increasing the radiotherapy dose can result in improved local control for non-small-cell lung cancer
(NSCLC) and can thereby improve survival. Accelerated hypofractionated radiotherapy can expose tumors to a high
dose of radiation in a short period of time, but the optimal treatment regimen remains unclear. The purpose of this
study was to evaluate the feasibility of utilizing high-dose accelerated hypofractionated three-dimensional
conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy
for the treatment of local advanced NSCLC.
Methods: Untreated patients with unresectable stage IIIA/IIIB NSCLC or patients with a recurrence of NSCLC
received accelerated hypofractionated three-dimensional conformal radiotherapy. The total dose was greater than
or equal to 60 Gy. The accelerated hypofractionated radiotherapy was conducted once daily at 3 Gy/fraction with 5
fractions per week, and the radiotherapy was completed in 5 weeks. In addition to radiotherapy, the patients also
received at least 1 cycle of a concurrent two-drug chemotherapy regimen of NVB and CBP.
Results: A total of 26 patients (19 previously untreated cases and 7 cases of recurrent disease) received 60Gy-75Gy
radiotherapy with concurrent chemotherapy. All of the patients underwent evaluations for toxicity and preliminary
therapeutic efficacy. There were no treatment-related deaths within the entire patient group. The major acute
adverse reactions were radiation esophagitis (88.5%) and radiation pneumonitis (42.3%). The percentages of grade
III acute radiation esophagitis and grade III radiation pneumonitis were 15.4% and 7.7%, respectively. Hematological
toxicities were common and did not significantly affect the implementation of chemoradiotherapy after supportive
treatment. Two patients received high dose of 75 Gy had grade III late esophageal toxicity, and none had grade IV
and above. Grade III and above late lung toxicity did not occur.
Conclusion: High-dose accelerated hypofractionated three-dimensional conformal radiotherapy with a dose of
60 Gy or greater with concurrent NVB and CBP chemotherapy might be feasible. However esophagus toxicity needs
special attention. A phase I trial is recommended to obtain the maximum tolerated radiation dose of accelerated
hypofractionated radiotherapy with concurrent chemotherapy.
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Concurrent chemoradiotherapy is one of the main means
of treatment for locally advanced non-small-cell lung
cancer (NSCLC) [1] and has been proven to be superior
to sequential chemotherapy and radiotherapy [2]. Cur-
rently, it is believed that concurrent chemoradiotherapy
improves survival mainly by improving local control [3].
Therefore, increasing the radiation dose can further im-
prove local control and subsequently improve survival.
Dose-escalation studies of conventional fractionated
radiotherapy with concurrent chemotherapy demonstrated
that, although phase I/II trials reported encouraging sur-
vival outcomes obtained with the high dose of 74 Gy [4,5],
the results of the subsequent phase III randomized
controlled study were disappointing and difficult to com-
prehend. The survival outcomes for the 74 Gy high-dose
group were not improved or were even less favorable than
the 60 Gy standard-dose group, with 1-year overall survival
(OS) rates of 70.4% and 81%, respectively. The preliminary
analysis revealed no significant differences in toxicity be-
tween the high-dose group and the low-dose group [6];
therefore, the above OS results cannot be explained by ex-
cessive treatment toxicity for the high-dose group. NSCLC
is a rapidly proliferating cancer, and accelerated repopula-
tion occurs during radiotherapy. If the treatment duration
extends for longer than 6 weeks, each additional day of
treatment is associated with a 1.6% decrease in survival [7].
Although the exact reasons why high-dose radiotherapy in
the Radiation Therapy Oncology Group (RTOG) 0617
study failed to produce survival benefits remain unclear,
one potential factor that should be considered is the
long treatment time of 7.4 weeks for the conventional
fractionation [1].
If the radiation dose for each fraction is increased, and
the entire radiotherapy regimen is completed with 25
fractions and within the total treatment time of 5 weeks,
this radiotherapy regimen could lead to a 10%-15%
greater local control than that of conventional fraction-
ated radiotherapy at 2 Gy/fraction without increasing
late toxicity [7]. Because accelerated hypofractionation
can significantly shorten the total treatment time and re-
duce the number of treatments, as well as provide the
advantages of convenience and economy, the regimen of
hypofractionated radiotherapy and concurrent chemo-
therapy should have good clinical prospects in theory.
However, due to concerns of treatment-related toxicity,
there have been a limited number of reports on hypo-
fractionated radiotherapy with concurrent chemotherapy.
With the advances in modern precision radiotherapy tech-
niques and the widespread clinical application of these
regimens [8], the three-dimensional conformal radiother-
apy technique can be used to conduct hypofractionated
radiotherapy, which can significantly lower the radiation
doses that normal tissues receive and thereby make itpossible to combine radiotherapy with concurrent chemo-
therapy [9-13].
For locally advanced NSCLC, a 3-Gy dose of acceler-
ated hypofractionated radiation alone is often applied
[14-17], and under certain conditions, the radiation dose
can be increased to 75 Gy [17]. To our knowledge, there
have been no reports regarding phase I/II studies for
hypofractionated radiotherapy at 3 Gy/fraction with con-
current chemotherapy. The maximum dose to which the
radiotherapy can be escalated is thus unclear. The purpose
of our prospective small-sample study was to evaluate the
feasibility of utilizing high-dose accelerated hypofrac-
tionated three-dimensional conformal radiotherapy (at 3
Gy/fraction) with concurrent vinorelbine (NVB) and
carboplatin (CBP) chemotherapy for the treatment of
locally advanced NSCLC.Methods
Inclusion criteria
Patients either had been pathologically or cytologically
confirmed to have previously untreated NSCLC and were
at the clinical stage of unresectable stage IIIA or stage IIIB
NSCLC [as defined by the 2009 staging standards of the
International Union Against Cancer (UICC)] or had a re-
currence after surgery. The patients were aged older than
or equal to 18 years and no more than 75 years. The
Karnofsky performance status (KPS) scores were at least
70, and the expected survival time was at least 3 months.
The laboratory test results were as follows: neutrophil
counts were 2.0×109/L; hemoglobin levels were at least
100 g/L; platelet counts (PLTs) were at least 100×109/L;
and serum creatinine, alanine aminotransferase, aspartate
aminotransferase, and total bilirubin levels were below the
upper limit of the normal range. The patients exhibited no
significant electrocardiographic (ECG) abnormalities, had
no history of serious heart disease, could receive concur-
rent chemoradiotherapy, and did not require hospital-
ization for diseases other than NSCLC.Exclusion criteria
Patients were excluded from the study if they were preg-
nant or lactation or had other malignancies (with the
exception of cases of cervical carcinoma in situ or non-
malignant melanoma skin cancer that had been clinically
cured for at least 5 years). Patients who could not
undergo concurrent chemoradiotherapy for medical rea-
sons or who suffered from either superior vena cava
syndrome or severe lung disorders that affected lung
function were also excluded.
This clinical trial was approved by the Ethics Committee
of Hebei Medical University. This study was performed in
accordance with the standards for human clinical trials
and the principles stated in the Declaration of Helsinki (as
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signed an informed consent form prior to enrollment.
Patient assessment
Patients underwent assessments within 2 weeks prior to
the treatment, including a complete medical history, a com-
prehensive physical examination, head, thoracic and ab-
dominal contrast-enhanced computed tomography (CT) or
magnetic resonance imaging (MRI) of the head, an ECG, a
bronchoscopy, routine blood testing, and a comprehensive
blood biochemical profile. If clinically indicated, a whole-
body bone scan was performed with emission CT (ECT).
The patients received physical examinations and had
routine blood testing performed each week (with an in-
creased frequency of examinations if necessary). Full
biochemical profiles were obtained and an ECG was
performed prior to each chemotherapy cycle.
Study design
This study was a single-arm, prospective, non-randomized
feasibility study. The primary research aim was to inves-
tigate whether accelerated hypofractionated three-
dimensional conformal radiotherapy (at 3 Gy/fraction)
with a total dose of 60 Gy or greater with concurrent
NVB and CBP chemotherapy could be safely applied.
The secondary aims included investigation of the short-
term efficacy, the progression-free survival (PFS), and
the OS. The chemoradiotherapy treatment scheme is
depicted in Table 1.
Radiation therapy
The patients were in the supine position with their
hands folded on top of their heads. A vacuum pad was
used to immobilize the patient’s body position and appro-
priately limit respiratory motion. Contrast-enhanced spiral
CT (Volume Computed Tomography, GE Healthcare,
Milwaukee, WI, USA) was performed in the same body
position as the treatment. The image data were input into
the three-dimensional treatment planning system. TheTable 1 Concurrent chemoradiotherapy schema
Concurrent chemoradiotherapy schema
RT regimen: Weeks 1–5: 3 Gy/f, 1 f/d,5 f/w;
Week 1 2 3
RT ┃┃┃┃┃ ┃┃┃┃┃ ┃┃┃┃
Chemotherapy: NVB (25 mg/m2) d1, d8; CBP, AUC = 5 mg/m1.min on d8, re
NVB ◆ ◆
CBP ●Venus 5014 software package (Shanghai Tuoneng Co.,
Shanghai, China) was used to design the radiotherapy
plan, which utilized convolution algorithms. The delinea-
tion of the thoracic lesion target area was performed in
accordance with the consensus guidelines for the delinea-
tion of target areas in NSCLC [18] as follows: the target
area of the primary lesion in the lung was delineated in
the lung window [1600, –600 Hounsfield units (HU)], and
the mediastinal target area was delineated in the medias-
tinal window (400, 20 HU). The treatment regimen uti-
lized involved-field irradiation without elective nodal
irradiation (ENI). The target volumes were defined as fol-
lows: the gross tumor volume (GTV) was defined as the
primary lesion in the lung or lymph nodes with a short
diameter greater than 1 cm in the CT image; the clinical
target volume (CTV) was defined as the GTV enlarged by
margins of 8 mm (in cases of adenocarcinoma) or 6 mm
(in cases of other pathologic types, such as squamous cell
carcinoma and metastatic lymph nodes); and the planning
target volume (PTV) was defined as the CTV enlarged by
a margin of 10 mm to 15 mm based on the respiratory
movement observed in the simulator. The GTV was de-
termined by two radiation oncologists and one diagnostic
imaging specialist. Two radiation oncologists outlined vital
organs and body surface contours. Three to six coplanar
fields were utilized for the conformal radiation. Dose-
volume histograms (DVHs) were used to optimize the
therapeutic plan. The treatment utilized 6 MV X-rays
from a Siemens Primus Plus linear accelerator that was
equipped with a 27-pair multi-leaf collimator (Topsla
ne@_M, Shanghai Tuoneng Co., Shanghai, China).
The full course of accelerated hypofractionated radio-
therapy for the thoracic lesions was conducted once
daily at 3 Gy/fraction with 5 fractions per week, and this
radiotherapy regimen was completed in 4–5 weeks.
Supraclavicular lymph node metastases received mixed
irradiation with X-rays and electron rays with a conven-
tional fraction of 2 Gy/fraction, once/day, 5 fractions/
week, and the total dose was 60–70 Gy.Dose level
4 5 6




peated every 28 d
◆ ◆
●
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Regarding the radiation received by vital organs, the fol-
lowing limiting conditions were employed: the V20 (the
percentage of healthy organ volume that receives 20 Gy
radiation) for both lungs was no more than 30%; 0% of
the esophagus was permitted to receive more than 70
Gy of radiation; a maximum of 10 cm of the esophagus
was permitted to receive 60 Gy or more of radiation; 0%
of the spinal cord was permitted to receive more than
40 Gy of radiation; and the V40 for the heart was no
more than 40% [19]. Under the above constraints, the
highest possible dose of radiation was applied, but the
maximum dose did not exceed 75 Gy.
Chemotherapy
Chemotherapy began on the first day of radiotherapy.
NVB was administered by intravenous infusion at a dose
of 25 mg/m2 on day 1 (d1) and day 8 (d8). CBP was ad-
ministered at an area under the concentration-time
curve (AUC) of 5 mg/ml on d8. This treatment was re-
peated every 28 days. At least 1 cycle of chemotherapy
was performed concurrently with the radiotherapy. After
the radiotherapy, the patients received a maximum of 4
cycles of consolidative chemotherapy, which utilized the
same chemotherapy regimen that was employed during
the concurrent chemoradiotherapy [19]. Anti-emetics,
hepatoprotective drugs, and other treatments were also
administered.
Supportive care
To ensure the smooth implementation of the chemo-
radiotherapy regimen, patients whose absolute neutro-
phil count (ANC) decreased to less than 2.0 × 109/L
were administered granulocyte colony-stimulating factor
(G-CSF) therapy until their ANCs increased to above
normal levels. Patients with PLTs of less than 75 × 109/L
received interleukin-11 therapy until the PLTs increased
to at least normal levels. If the patients developed
esophageal symptoms, like dysphagia and odynophagia,
0.9% sodium chloride solution containing dexametha-
sone and lidocaine was immediately given to relieve the
symptoms including pain and dysphagia, and to reduce
the probability of the occurrence of severe esophagitis.
Nutritional support via intravenous rehydration was also
provided to patients as needed.
Evaluation of adverse reactions
The Common Terminology Criteria for Adverse Events
(CTCAE), version 3.0, which was issued by the National
Cancer Institute/National Institutes of Health (NCI/NIH),
was used as the standard for the evaluation of treatment
toxicity. Weekly assessments of toxicity were conducted
during the concurrent chemoradiotherapy treatment.
Adverse events that occurred within 90 days from thebeginning of radiotherapy were classified as acute toxicity,
and those that occurred more than 90 days after the be-
ginning of radiotherapy were classified as late toxicity.
Evaluation of the short-term efficacy of tumor treatment
The evaluation of the short-term treatment efficacy was
based on the thoracic-abdominal spiral CT examination
results at 4 weeks after the completion of the radiother-
apy. The Response Evaluation Criteria in Solid Tumors,
version 1.1, (RECIST 1.1) standard was utilized for these
assessments [20].
Dose attenuation
Dose attenuation was implemented based on the most
serious adverse events that occurred at any point after
the start of the treatment.
Because we were conducting a feasibility study of high
dose radiotherapy, no reductions in radiation dose were
permitted. However, if a toxicity of grade III or higher
occurred (with the exception of grade III nausea,
vomiting, or weight loss), the radiotherapy was postponed
until the toxicity had resolved. In contrast, if adverse
events unrelated to radiotherapy occurred, such as periph-
eral neuropathy, the radiotherapy was continued, but the
chemotherapy was suspended. The chemotherapy was re-
sumed after these adverse events had dissipated.
The chemotherapy dose-adjustment procedures were
as described below. Both radiotherapy and chemotherapy
were suspended until the toxicity had resolved in the case
of grade III/IV thrombocytopenia, grade III/IV anemia,
grade IV neutropenia, or grade III/IV non-hematologic
toxicities (except for grade III nausea, vomiting, or weight
loss). If the toxicity had not resolved within 2 weeks, the
patient was then excluded from the study. The NVB and
CBP doses of the next chemotherapy cycle were reduced
by 25%, and the patient received prophylactic G-CSF
treatment. In the case of grade III neutropenia or grade II
thrombocytopenia alone, chemotherapy was stopped, but
the radiotherapy was continued. The NVB and CBP doses
of the next chemotherapy cycle remained unchanged, and
the patient received prophylactic G-CSF treatment.
Follow-up and statistics
A follow-up was conducted every 3 months for the first
2 years after the completion of the radiotherapy and
every 6 months thereafter. All of the statistical analyses
were performed using the SPSS 19.0 biostatistical soft-
ware package. The survival data were evaluated with the
Kaplan-Meier method. The survival time was measured
from the initiation of the concurrent chemoradiotherapy
until death due to any cause or the subsequent follow-
up event. Only the first treatment failure was taken into
account. PFS was defined as survival without local recur-
rence or distant metastases.
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Patient characteristics
From June 2010 to August 2012, 27 patients with patho-
logically or cytologically confirmed NSCLC were enrolled
in this study. Twenty cases had previously untreated
NSCLC, and 7 cases had recurrent NSCLC. Of these, 26
patients received toxicity and efficacy evaluations (1 pa-
tient withdrew from the study due to personal reasons, ra-
ther than treatment toxicity). The clinical data for these
patients are provided in Table 2. The median age was 68
years, and the median KPS score was 80. The cases in-
cluded 9 cases of squamous cell carcinoma, 11 cases of
adenocarcinoma, 2 cases of large cell carcinoma, 1 case of
adenosquamous carcinoma, 1 case of sarcoma, and 2 cases
of undifferentiated carcinoma. The 19 patients with previ-
ously untreated NSCLC included 6 cases of stage IIIA and
13 cases of stage IIIB (including 6 cases of supraclavicular

















Squamous cell carcinoma 9 34.6
Adenocarcinoma 11 42.3
large cell carcinoma 2 7.7
Adenosquamous carcinoma 1 3.8
sarcoma 1 3.8













Among the 20 patients with previously untreated NSCLC,
1 patient refused to continue treatment due to personal
reasons, rather than treatment toxicity. This patient re-
ceived only 15 Gy of radiotherapy and one cycle of NVB
chemotherapy before withdrawing and could not be evalu-
ated. However, 26 patients completed the radiotherapy
with dose levels of 60 Gy-75 Gy. The 60 Gy, 63 Gy, 69 Gy,
and 75 Gy groups included 12, 3, 6, and 5 participants,
respectively, as presented in Table 3. Among the 26 pa-
tients who completed at least one cycle of concurrent
chemotherapy, all received consolidative chemotherapy
with a median of 4 chemotherapy cycles (with a range of
1 to 4 cycles).
Toxicity
Table 4 contains the acute and late toxicities. No pa-
tients within the entire group had treatment-related
death (Grade V). The common radiation-related toxic-
ities included radiation esophagitis and radiation pneu-
monitis, but most of these toxicities were mild to
moderate and could be easily treated in clinical practice.
Except for 3 cases, all of the patients had esophagitis,
and the total incidence was 88.5%. There were 4 pa-
tients with grade III esophagitis; 3 out of the 4 patients
received a radiotherapy dose of 75 Gy, and the other pa-
tient received 69 Gy. Among the 3 patients in the 75 Gy
group, the esophagus of 2 patients received a radiation
dose as high as 75 Gy, which was above the pre-set con-
straints (less than or equal to 70 Gy). These 2 patients
developed grade III late toxicities, and the esophageal
stricture affected eating; therefore, esophageal dilatation
was required. Late esophageal toxicity was generally
mild and occurred in only 5 cases (19.2%). Except for
the 2 cases who received the highest radiation dose of
75 Gy, the rest developed grade I/II conditions. Severe
acute radiation pneumonitis was rare, with only 2 cases
of grade III (7.7%). No grade III and above late pulmon-
ary fibrosis occurred.
All (100%) of the patients exhibited neutropenia, and
30.8% exhibited grade III/IV neutropenia. In contrast,
grade III/IV thrombocytopenia and anemia were rare.
Nausea, fatigue, and loss of appetite were observed in
most of the patients. However, these effects were mild to
moderate and were successfully alleviated through the ad-
ministration of appropriate antiemetics and intravenousTable 3 Patients in different groups of radiation dose





Table 4 Acute and late toxicities
Item Grade I Grade II Grade III Grade IV Total
Case % Case % Case % Case % Case %
Acute
Radiation pneumonia 5 19.2 4 15.4 2 7.7 0 0 11 42.3
Cough 6 23.1 3 11.5 2 7.7 0 0 11 42.3
Radiation oesophagitis 10 38.5 9 34.6 4 15.4 0 0 23 88.5
Radiation dermatitis 3 11.5 2 7.7 0 0 0 0 5 19.2
Nausea 8 30.8 10 38.5 6 23.1 0 0 24 92.3
Vomiting 6 23.1 3 11.5 1 3.8 0 0 11 42.3
Anorexia 12 46.2 10 38.5 3 11.5 0 0 25 96.2
Fatigue 10 38.5 8 30.8 2 7.7 0 0 20 76.9
Neutropenia 4 15.4 14 53.8 5 19.2 3 11.5 26 100
Thrombocytopenia 8 30.8 4 15.4 1 3.8 0 0 13 50
Anemia 6 23.1 3 11.5 0 0 0 0 9 34.6
ALT 4 15.4 1 3.8 0 0 0 0 5 19.2
AST 3 11.5 0 0 0 0 0 0 3 11.5
Cr 1 3.8 0 0 0 0 0 0 1 3.8
BIL 2 7.7 0 0 0 0 0 0 2 7.7
Late
Lung 12 46.2 4 15.4 0 0 0 0 16 61.5
Esophagus 1 3.8 2 7.7 2 7.7 0 0 5 19.2
Skin 1 3.8 0 0 0 0 0 0 1 3.8
ALT alanine aminotransferase, AST aspartate aminotransferase.
Cr serum creatinine, BIL bilirubin.
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moradiotherapy. Liver and kidney toxicity was rare.Short-term treatment efficacy
Evaluations of the short-term treatment efficacy for the
26 cases were as follows: complete response (CR) 26.9%
(7/26), partial response (PR) 53.8% (14/26), stable disease
(SD) 19.2% (5/26), and no progressive disease (PD). The
total response rate (RR) was 80.8% (21/26).Survival
Although this study is a feasibility study, we nonetheless
determined preliminary survival results. The median
follow-up period was 11.5 months (4 months-23 months),
the median PFS was 10 months, and 37.0% of the study
participants achieved a 1-year PFS (Figure 1). The median
OS was 13 months, and 60.9% of the study participants
achieved 1-year OS (Figure 2). Eleven cases survived, and
15 cases died. The reasons for treatment failure were as
follows: 3 cases had residual cancer or a recurrence within
the radiation field; 2 cases had a recurrence within the ra-
diation field and distant metastasis; and 13 cases had dis-
tant metastases ( 3 cases of liver metastasis, 3 cases of
bone metastasis, 2 cases of brain metastasis, 1 case of ad-
renal metastasis, and 4 cases of multiple metastases). Thetreatment failure was mainly due to distant metastases,
which was up to 72.2% (13/18).
Discussion
NSCLC is a type of rapidly proliferating tumor. Studies
have demonstrated that the median potential cell doub-
ling time is 7 days [21], and accelerated proliferation
occurs in the 3rd week-4th week of radiotherapy [22],
which is one of the important reasons for NSCLC radio-
therapy failure. If sufficient radiation is applied within a
short period of time, this approach might overcome the
accelerated repopulation. Accelerated hypofractionated
radiotherapy can shorten the total treatment time, apply
a high-dose of radiation in a short period of time,
improve the biological effective dose (BED), and play an
important role in the treatment of NSCLC [21]. How-
ever, due to the concerns of severe late toxicity, acceler-
ated hypofractionated radiotherapy is not yet widely
applied for the treatment of NSCLC. With improved
three-dimensional conformal and intensity-modulated
radiotherapy technologies, it is possible to accurately
irradiate the target area while significantly reducing the
radiation dose received by the surrounding normal
tissues and organs [9]. Therefore, it is necessary to re-
evaluate the tolerance for accelerated hypofractionated
radiotherapy.
Figure 1 The median PFS time was 10 months, and 1- year PFS
rate was 37.0%.
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of 80 Gy-100 Gy was required to cure lung cancer.
Dose-escalation studies of three-dimensional conformal
radiotherapy showed that in the 63 Gy-103 Gy range, a
high radiation dose increased local control of the
tumor and OS [24]. The clinical practice of stereotactic
body irradiation for NSCLC yielded the same results:
the survival of patients who received radiotherapy at a
BED of at least 100 Gy was significantly better than
those who received a BED of less than 100 Gy [25].Figure 2 The median OS time was 13 months, and 1- year OS
rate was 60.9%.The dose of radiation can significantly affect the
NSCLC treatment result.
Thirion et al. [26] conducted a study of high-dose ac-
celerated hypofractionation at 3 Gy/fraction in which a
72 Gy radiation dose was delivered in 24 fractions over 5
weeks. The regimen was tolerated. One of the study par-
ticipants experienced grade III radiation pneumonitis, 2
experienced grade III radiation esophagitis, and no grade
IV or higher adverse events occurred among the entire
group of participants. Xie et al. [16] performed a dose-
escalation trial of accelerated hypofractionated radio-
therapy at 3 Gy/fraction with cases from the Chinese
population and found that patients tolerated the radio-
therapy treatment at doses of up to 75 Gy at V20 levels
no greater than 20% or at doses of up to 69 Gy at V20
levels between 20% and 30%.
It has been confirmed in the conventional fractionated
radiotherapy of NSCLC that radiotherapy combined with
chemotherapy is superior to radiotherapy alone. In vitro
studies suggest that the combination of radiotherapy and
chemotherapy can significantly increase the biological
effects of hypofractionated radiotherapy [27]. Therefore,
in theory, hypofractionated radiotherapy combined with
chemotherapy should also be superior to hypofractionated
radiotherapy alone. The Fudan University Cancer Center
reported the results of a Phase II trial of hypofractionated
radiotherapy with sequential chemotherapy. The first half
of radiotherapy utilized a radiation dose of 50 Gy with 2.5
Gy fractions, and the dose was subsequently increased to
3 Gy/fraction to a total radiation dose of 65 Gy to 68 Gy,
although ENI was not performed. All of the study par-
ticipants received 2 cycles of induction chemotherapy
with sufficient doses of NVB and cisplatin, and good
treatment efficacy was observed. The median PFS, the
median OS, and the 3-year OS rate were 10 months,
19.0 months, and 32.1%, respectively, with acceptable
treatment toxicities [28].
Among the limited number of studies focused on
hypofractionated radiotherapy with concurrent chemo-
therapy, each study utilized different fractionation and
chemotherapy regimens [9-13]. The European studies
used 2.75 Gy/fraction [9-12], while the South Korean
study [13] applied 2.4 Gy/fraction [the simultaneous
modulated accelerated radiation therapy (SMART) boost
technology]. It is noteworthy that all three studies sug-
gested that the toxicity could be tolerated and that
hypofractionation did not seem to significantly increase
the late toxicity, which is consistent with our conclusion.
The study with the largest sample size was the European
Organization for Research and Treatment of Cancer
(EORTC) phase III trial [10], which had a total of 158
enrolled patients. Because the regimen for the concur-
rent group utilized concurrent daily low-dose cisplatin
treatment, the hematologic toxicity of the concurrent
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group (provided the dose of chemotherapy was suffi-
ciently high). Despite the application of ENI, the rate of
grade III acute esophagitis in the EORTC study was
similar to our study, 14% vs. 15.4%. In contrast, the rate
of late esophageal toxicity in the EORTC study was
lower than in our study, and the rates in the EORTC
study and our results were 4% and 7.7%, respectively.
The EORTC study had 2.75 Gy fractions and a relatively
high total dose of 66 Gy, and in addition, that study uti-
lized ENI. The mild toxicity observed in the EORTC
study results might be related to the low doses of con-
current chemotherapy. The EORTC study indicated that
the survival of the concurrent chemoradiotherapy group
was not superior to that of the sequential group. This re-
sult might be due to the low-dose single-agent chemo-
therapy because some studies have suggested that the
intensity of the chemotherapy dose is critical for concur-
rent chemoradiotherapy [29].
In our study, a relatively high radiation dose of 60 Gy-
75 Gy was completed within 4 weeks-5 weeks. Five pa-
tients completed radiotherapy with doses up to 75 Gy.
In addition, 2 patients received esophageal doses beyond
our pre-determined constraints of esophageal dose, and
the highest esophageal doses were both 75 Gy. These 2
patients both completed the full radiotherapy dose with
persistent dysphagia. The grade III esophageal late toxic-
ities that occurred 3 months later were esophageal sten-
oses, which necessitated esophageal dilatation. Until the
last follow-up, the 2 patients were free of local progres-
sion. Among the remaining 3 patients whose esophageal
doses did not exceed the constraints, 1 patient had grade
III acute esophagitis that gradually dissipated after the
end of the radiotherapy, and no late esophageal toxicity
of grade III and above occurred. The radiotherapy at a
dose of 75 Gy caused esophageal stenosis in 40% (2/5) of
the patients within a short period of time, which should
have been paid much more attention. Given that the
radiotherapy at a dose of 75 Gy was performed in five
patients along with a short follow-up, the safety of the
radiotherapy at a dose of 75 Gy remains unknown. Prior
to the publication of the phase I/II clinical trial results,
the radiotherapy at a dose of 75 Gy should be avoided.
All 5 patients had V20 below 30%, and there was 1 case
of grade III acute radiation pneumonitis. No grade III or
above late radiation-induced lung injury occurred among
the entire group of participants. The main acute toxicities
of all 26 patients were radiation esophagitis and pneumo-
nia, which accounted for 88.5% (23/26) and 42.3% (11/26),
respectively. Although the incidences of nausea, anorexia,
and fatigue were high, these conditions did not affect the
implementation of the chemoradiotherapy. Hematologic
toxicity was common due to the sufficiently high doses of
concurrent chemotherapy, with incidences of up to 100%for neutropenia, 50% for thrombocytopenia, and 34.6% for
anemia. Because of our close monitoring and positive
symptomatic and supportive treatment measures, there
were no patients who had more than 7 days of interrup-
tion in the radiotherapy due to toxic effects. Due to the
small sample size and short follow-up period, further
longer term follow-up observations with larger sample
size will be required in order to investigate the final
safety and long-term toxicity for this treatment regimen.
Based on the toxicity from the present study, an acceler-
ated hypofractionated radiotherapy at a dose of 60 Gy
or greater with concurrent chemotherapy with the NC
scheme might be feasible.
The total incidence of the acute esophagitis in our study
was as high as 88.5% (23/25), including 38.5% (10/25)
grade I, 34.6% (9/25) II, and 15.4% (4/25) grade III esopha-
gitis, which were comparable to those observed in several
previous similar studies. A study conducted in South
Korea reported a 81.6% (40/49) of total esophagitis and a
14.3% (7/49) incidence of the grade III/IV esophagitis fol-
lowing the involved-field radiotherapy [13]. In two studies
of SOCCAR, the incidence of grade III esophagitis was
9.0% (6/67) and 13.3% (4/30), respectively with no grade
IV or greater occurred [11,12]. Hypofractionated irradi-
ation theoretically does not increase acute complications.
The incidence of acute esophagitis in the current study
was similar to what was observed in the conventional
fractionated radiotherapy with concurrent chemotherapy.
Furuse et al. [30] reported that the incidence of total acute
esophagitis was 62.8% (98/156) with a 2.6% (4/156) inci-
dence of grade III esophagitis. Furthermore, Zatloukal
et al. detected a 18% incidence of grade III/IV esophagitis
[31]. Our previous study reported a 78.4% (29/37) inci-
dence of total esophagitis and a 13.5% (5/37) incidence of
grade III acute esophagitis in the conventional 70-Gy frac-
tionated radiotherapy with concurrent vinorelbine plus
carboplatin chemotherapy [32]. A meta-analysis of seven
clinical trials revealed a grade III/IV acute esophagitis in
18% of the 1077 patients [3].
However, there have been some studies reporting a
significantly higher incidence for the acute radiation
esophagitis (grade III or greater) as compared to what was
observed in the current study. In the RTOG 94–10 study,
the incidence of the grade III/IV radiation esophagitis was
reported to be 23% (43/193) following the conventional 63
Gy fractionated radiotherapy [33]. In the NPC 95–01
study, the incidence of the grade III/IV radiation esopha-
gitis was 32% following the conventional 66 Gy fraction-
ated radiotherapy [34]. The high incidence of the radiation
esophagitis in these two studies might have been associ-
ated with the preventive radiation of the lymph drainage
area. In the RTOG 94–10 study, the radiotherapy at a dose
of 45 Gy was given to the lymph drainage area [33]. In the
NPC 95–01 study, a larger area received the radiation,
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and the homolateral supraclavicular fossa if the lesions oc-
curred in the upper lobe of the lung. Furthermore, the
paraesophageal and inferior pulmonary ligament nodal re-
gions were exposed to radiation if the lesions occurred in
the lower lobe of the lung [34]. This could significantly
contribute to the radiation volume enhancement and an
increased esophagus radiation dose, which could result in
a high incidence of esophagitis.
In the current study, only the primary lesions with the
mean gross tumor volume (GTV) of 98.1 (range, 30.2-
238.7) cm3 and mean planning target volume (PTV) of
248.4 (range, 132.6-396.5) cm3 received the radiother-
apy, resulting in a low radiation dose for the esophagus.
The concurrent chemotherapy with the involved-field
radiation technique at a dose of 74 Gy caused a relatively
low incidence of severe acute radiation esophagitis. The
RTOG 1107 study reported an 11.1% (1/9) incidence of
esophagitis [4], while there was no occurrence of the grade
III/IV esophagitis (0/6) in the NCCTGN 0028 study [5].
The incidence of grade III esophagitis was 16% (6/37) in
the CALGB 30105 study, while no grade IV or greater
esophagitis was observed [35]. Harada et al. reported the
patients undergoing radiotherapy at a dose of 74 Gy did
not develop the grade III/IV esophagitis (0/12) [36].
The EORTC study results indicated that the median
survival time of the concurrent group was 16.5 months
[10], similar to the median survival time of our study,
which was of 13 months. The survival time in our study
is significantly lower than the other two studies, which
were 27.4 months [11] and 28.1 months [13], respect-
ively. We believe that this result can be explained in the
following ways: the South Korean study [13] and the
United Kingdom study [11] were more stringent in
selecting the enrolled patients, which might lead to a bet-
ter prognosis. For example, the patient selection criteria
required that the Eastern Cooperative Oncology Group
(ECOG) score was 0–1 with the majority of patients hav-
ing an ECOG score of 0. The patients were also required
to have good lung function with a forced expiratory vol-
ume in 1 second (FEV1) of no less than 1 L or 0.75 L, etc.
However, our study was a feasibility study. Regarding the
performance status score, we only required that the KPS
score was not less than 70, namely, the patients could take
care of themselves most of the time. Furthermore, we had
no explicit requirements for the FEV1, as long as the
patients could receive chemoradiotherapy. The South
Korean study [13] eliminated some poor prognostic fac-
tors, such as supraclavicular lymph node metastasis
(which occurred in 6 patients in our study) and superior
vena cava syndrome. In the United Kingdom study [11],
squamous cell carcinoma accounted for 64% of all of
the participants. Because squamous cell carcinoma is
relatively less prone to distant metastasis, concurrentchemoradiotherapy might achieve better survival out-
comes [37]. Of the patients who we enrolled in this
study, 26.9% of them presented with a postoperative
recurrence, which itself indicated a poor prognosis.
Nevertheless, our concurrent chemoradiotherapy regi-
men still achieved a RR of 80.8%, the median and 1-year
PFS values were 10 months and 37.0%, respectively, and
the median and 1-year OS were 13 months and 60.9%, re-
spectively. We believe that the current hypofractionated
chemoradiotherapy regimen archives moderate efficacy
and these survival results are acceptable.
The 3 hypofractionated concurrent chemoradiotherapy
studies [10,11,13] noted above differed greatly from our
study in the fractionation scheme and concurrent chemo-
therapy drugs. The doses per fraction used in the above 3
studies [10,11,13] and in our study were 2.4 Gy, 2.75 Gy,
2.75 Gy, and 3 Gy, respectively. The concurrent chemo-
therapy regimens included daily low-dose cisplatin [9,10],
weekly paclitaxel and CBP [13], sufficient doses of NVB
and cisplatin [11,12], and NVB and CBP (our study). It is
difficult to compare directly the advantages and disadvan-
tages of these chemotherapy regimens. From the existing
literature, it is impossible to identify the optimal regimen
of accelerated hypofractionated radiotherapy with concur-
rent chemotherapy or the maximum radiation dose to
which the dose of accelerated hypofractionated concurrent
chemoradiotherapy could be escalated.
In NSCLC radiotherapy and/or chemoradiotherapy,
the lung is one of the most critical limiting organs. Stud-
ies focusing on the tolerated radiation dose of the lung
are the most numerous and most mature. Because the
lung is a parallel organ, its limiting dose is often mea-
sured by dose-volume parameters, such as V20 and Veff.
The dose escalation of radiotherapy for the treatment of
NSCLC often involves different bins of dose escalation
based on different dosimetric of lung irradiation dose-
volume. For patients with a smaller irradiation volume,
the dose could be incremented to 103 Gy [24]. There
are relatively fewer studies focusing specifically on the
limiting dose of the esophagus. The conclusions of dosi-
metric parameters, such as the esophageal length of ir-
radiation and radiation dose-volume, are not consistent
[38-42]. Even for hyperfractionated radiotherapy alone,
the esophagus is not considered to be a dose-limiting
organ [43]. However, hypofractionated radiotherapy can
theoretically increase late toxicity, and the esophagus must
be considered as one of the dose-limiting organs. Cur-
rently, there are no unified limiting-dose parameters that
can be applied to the esophagus. In the 2 European studies
of hypofractionated concurrent chemoradiotherapy, a
maximum of 12 cm of the esophagus in the PTV was per-
mitted to receive radiation [10,11]. The South Korean
study used the dose-volume parameters with V55 less than
or equal to 30% [13]. Because the esophagus has the
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believe that the highest radiation dose received by the
esophagus should also be considered. Based on the
esophageal limiting dose in our conventional fractionated
radiotherapy with concurrent chemotherapy, we chose the
restriction conditions of a maximum irradiated length of
10 cm and a maximum dose of 70 Gy [19]. Under these
constraints, the incidence of grade III and above acute
esophagitis was only 8.3% (2/24), and there were no grade
III and above late toxicities. In contrast, the 2 patients
who received the highest esophageal irradiation dose of
75 Gy both had grade III esophagitis and developed a
grade III late toxicity, which suggests that esophageal
toxicity is also related to the highest dose of radiation.
The various esophagitis evaluation criteria are not the
same (RTOG/EORTC 1995 and CTC standards). In
addition, the evaluation criteria for esophagitis, espe-
cially acute esophagitis, are quite subjective, and the
grades of radiation esophagitis determined by different
treatment centers might have significant differences.
We thus found it difficult to determine which limiting
dose of the esophagus was more reasonable and accur-
ate [9-13]. Based on the above reasons, it is also difficult
to determine the maximum tolerated dose in the ab-
sence of a unified esophageal limiting dose. Therefore,
some studies have suggested that when conducting a
dose escalation of radiotherapy for the treatment of
NSCLC, the principle of individualization should be ap-
plied, and each case should be given a different highest
dose so that each case would reach the maximum toler-
ated dose for normal tissue [43].
Conclusion
In China a large part of patients were worried about the
toxicity associated with the high-dose accelerated hypo-
fractionated radiotherapy with concurrent chemotherapy
that resulted in some difficulties in the recruitment.
Therefore, a small-sample exploratory study was carried
out. This study had three limitations, including: (1) Small
sample size, with only 27 cases involved. (2) Short follow-
up period, with the median follow-up period of only 11
months. (3) No strict inclusion/exclusion criteria for the
subjects, which might have led to unsatisfactory survival
outcomes. Therefore, a very definitive conclusion could be
hardly acquired from the results. However, this prospect-
ive, exploratory study firstly evaluated the safety of the ac-
celerated hypofractionated radiotherapy at a dose of >60
Gy with concurrent chemotherapy. The results suggested
that: first, under certain constraints for normal tissue,
high-dose hypofractionated three-dimensional conformal
radiotherapy (60 Gy or greater at 3 Gy/fraction) with con-
current NVB and CBP chemotherapy might be feasible.
Second, special attention should be paid to the esopha-
geal toxicity caused by the high-dose hyopfractionatedradiotherapy, particularly late toxicity. The safety of the
hypofractionated radiotherapy at a dose of 75 Gy re-
mains controversial. Therefore, the hypofractionated
radiotherapy at a dose of 75 Gy should be avoided be-
fore the publication of the clinical trial results could
verify its safety. Third, we recommend that an individu-
alized dose-escalation study should be carried out by
grouping patients based on the different risks of adverse
events to obtain the maximum tolerated dose of acceler-
ated hypofractionated concurrent chemoradiotherapy.
The constraints of the lung and the esophagus should
both be considered for radiotherapy dose escalation.
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